Full Press Release Details
In the case of Eli Lilly and Company v. Teva Parenteral Medicines, Inc., et al. , the court affirmed the earlier district court's rulings that the vitamin regimen patent is valid and would be infringed by the generic challengers' proposed products. If the patent is ultimately upheld through all remaining challenges, Alimta would maintain U.S. exclusivity until May 2022 , preventing marketing of generic products for as long as the patent remains in force. The Alimta compound patent remains in force through January 24, 2017 .
In March 2014 , the U.S. Court for the Southern District of Indiana upheld the validity of the vitamin regimen patent. In August 2015 , the same court ruled in Lilly's favor regarding infringement of the vitamin regimen patent.
About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels . C-LLY
This release contains forward-looking statements regarding the U.S. Alimta patent litigation. These statements are based on management's current expectations but actual results may differ materially. There can be no assurance that the company will prevail in any appeal. Also, the company cannot predict whether generic pemetrexed will be marketed prior to the expiration of the vitamin regimen patent. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission.
Alimta ® (pemetrexed, Lilly)
| Refer to: | Lauren Zierke; [email protected] ; (317) 277-6524 (Media) |
| Phil Johnson; [email protected] ; (317) 655-6874 (Investors) |
SOURCE Eli Lilly and Company